+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Large Molecule Drug Substance CDMO Market Size, Share & Trends Analysis Report By Service (Contract Manufacturing, Contract Development), By Source, By End-user, By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 145 Pages
  • November 2022
  • Region: Global
  • Grand View Research
  • ID: 5702088
Description Jump to:
The global large molecule drug substance CDMO market size is expected to reach USD 22.1 billion by 2030., expanding at a CAGR of 9.3% from 2023 to 2030. Rising incidence of infectious diseases and high demand for novel therapeutics are the key factors driving the market.

Contract manufacturing is one of the major steps in large molecule production and accounts for a sizable portion of the large molecule drug substance market. The mode of manufacturing is an important factor to consider because it represents the sector's outsourcing and in-house activities. Companies are now choosing to outsource services due to high costs and delays in time. This has resulted in a greater proportion of large molecules being outsourced by the firms. A contract development and manufacturing organization (CDMO) is a company that provides a comprehensive range of services to the pharmaceutical industry from drug development to manufacturing. CDMOs provide critical services by incorporating third-party projects and offering their knowledge, development, and manufacturing capabilities.

Prior to the COVID-19 pandemic, large molecule drug investment was increasing as it offers a plethora of new treatment options. The valuation of biologics became clearer during the race to develop therapeutics and vaccines against the SARS-CoV-2 virus. The demand for both high-volume and high-quality CGMP drug substance and drug product manufacturing services has risen dramatically, particularly for CDMOs capable of providing a wide range of COVID vaccine technologies and, to a lesser extent, therapeutic monoclonal antibody products.

Large Molecule Drug Substance CDMO Market Report Highlights

  • The contract manufacturing service segment dominated the market with a revenue share of over 65.0% in 2022
  • Based on source, the mammalian segment accounted for the largest share of over 55.0% in 2022. This category will expand as more complex biologics, such as bi- and tri-specific antibodies, and antibody-drug conjugates are evolved
  • Based on end-user, the biotech companies segment accounted for the largest share of over 40.0% in 2022. Rising R&D investment by the firms for large molecules drives the market
  • Asia Pacific is projected to register the fastest CAGR of 10.4% during the forecast period. The large patient base, lower overall costs, skilled workforce, and changes in the regulatory scenario are the key factors driving the market


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 service
1.1.2 Source
1.1.3 End-User
1.1.4 Regional Scope
1.1.5 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.3.5.1 Data For Primary Interviews In North America
1.3.5.2 Data For Primary Interviews In Europe
1.3.5.3 Data For Primary Interviews In Asia Pacific
1.3.5.4 Data For Primary Interviews In Latin America
1.3.5.5 Data For Primary Interviews In Mea
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.2 Volume Price Analysis (Model 2)
1.6.2.1 Approach 2: Volume Price Analysis
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Outlook
Chapter 3 Large Molecule Drug Substance CDMO Market: Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.1.2 Ancillary market outlook
3.2 Market Variable Analysis
3.2.1 Market driver analysis
3.2.1.1 Increasing large molecule drug approvals
3.2.1.2 Rising incidence of infectious diseases,
3.2.1.3 Higher capital investments by pharma and biotech firms in advanced technologies for establishing partnerships with CDMOs
3.2.2 Market restraint analysis
3.2.2.1 Compliance issues while outsourcing
3.2.2.2 Changing scenarios within developing countries
3.3 Large Molecule Drug Substance CDMO Market: Analysis Tools
3.3.1 Porter’s Five Forces Analysis
3.3.2 Pestel Analysis
3.3.3 Major Deals & Strategic Alliances Analysis
3.3.3.1 Mergers And Acquisitions
3.3.3.2 Expansions
3.3.3.3 Agreement & Collaborations
3.4 Covid-19 Impact and Reformation Analysis
Chapter 4 Large Molecule Drug Substance CDMO Market: Service Segment Analysis
4.1 Large Molecule Drug Substance CDMO Market: Definition & Scope
4.2 Large Molecule Drug Substance CDMO Market: Market Share Analysis, 2022 & 2030
4.3 contract Manufacturing
4.3.1 Contract Manufacturing Services Market, 2018 - 2030 (USD Million)
4.3.2 Clinical
4.3.2.1 Clinical, 2018 - 2030 (USD Million)
4.3.3 commercial
4.3.3.1 Commercial market, 2018 - 2030 (USD Million)
4.4 Contract Development
4.4.1 Contract Development Market, 2018 - 2030 (USD Million)
4.4.2 Cell Line Development
4.4.2.1 Cell Line Development Market, 2018 - 2030 (USD Million)
4.4.3 Process Development
4.4.3.1 Process Development Market, 2018 - 2030 (USD Million)
Chapter 5 Large Molecule Drug Substance CDMO Market: Source Segment Analysis
5.1 Large Molecule Drug Substance CDMO Market: Definition & Scope
5.2 Large Molecule Drug Substance CDMO Market: Market Share Analysis, 2022 & 2030
5.3 Mammalian
5.3.1 Mammalian Market, 2018 - 2030 (USD Million)
5.4 Microbial
5.4.1 Microbial Market, 2018 - 2030 (USD Million)
5.5 oOthers
5.5.1 Others Market, 2018 - 2030 (USD Million)
Chapter 6 Large Molecule Drug Substance CDMO Market: End-user Segment Analysis
6.1 Large Molecule Drug Substance CDMO Market: Definition & Scope
6.2 Large Molecule Drug Substance CDMO Market: Market Share Analysis, 2022 & 2030
6.3 Biotech Companies
6.3.1 Biotech Companies Market, 2018 - 2030 (USD Million)
6.4 CRO
6.4.1 CRO Market, 2018 - 2030 (USD Million)
6.5 Others (Pharma Companies, Government, Research Institutes, Academic Institutes, Etc.)
6.5.1 Others (Pharma Companies, Government, Research Institutes, Academic Institutes, Etc.) Market, 2018 - 2030 (USD Million)
Chapter 7 Large Molecule Drug Substance CDMO Market: Regional Analysis
7.1 Regional Market Snapshot
7.2 Large Molecule Drug Substance Cdmo Market: Market Share Analysis, 2022 & 2030
7.3 North America
7.3.1 North America Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.3.2 U.S.
7.3.2.1 U.S. Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.3.3 Canada
7.3.3.1 Canada Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.4 Europe
7.4.1 Europe Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.4.2 U.K.
7.4.2.1 U.K. Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.4.3 Germany
7.4.3.1 Germany Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.4.4 France
7.4.4.1 France Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.4.5 Italy
7.4.5.1 Italy Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.4.6 Spain
7.4.6.1 Spain Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.4.7 Denmark
7.4.7.1 Denmark Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.4.8 Sweden
7.4.8.1 Sweden Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.4.9 Norway
7.4.9.1 Norway Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.4.10 Rest Of Europe
7.4.10.1rest Of Europe Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.5 Asia Pacific
7.5.1 Asia Pacific Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.5.2 Japan
7.5.2.1 Japan Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.5.3 China
7.5.3.1 China Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.5.4 India
7.5.4.1 India Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.5.5 Australia
7.5.5.1 Australia Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.5.6 Thailand
7.5.6.1 Thailand Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.5.7 South Korea
7.5.7.1 South Korea Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.5.8 Rest Of Apac
7.5.8.1 Rest Of Apac Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.6 Latin America
7.6.1 Latin America Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.6.2 Brazil
7.6.2.1 Brazil Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.6.3 Mexico
7.6.3.1 Mexico Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.6.4 Argentina
7.6.4.1 Argentina Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.6.5 Rest Of Latam
7.6.5.1 Rest Of Latam Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.7 Mea
7.7.1 Mea Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.7.2 South Africa
7.7.2.1 South Africa Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.7.3 Saudi Arabia
7.7.3.1 Saudi Arabia Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.7.4 Uae
7.7.4.1 Uae Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.7.4 Kuwait
7.7.4.1 Kuwait Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
7.7.4 Rest Of MEA
7.7.4.1 rest Of Mea Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
Chapter 8 Company Profiles
8.1.1 Thermo Fisher Scientific Inc.
8.1.1.1 Company Overview
8.1.1.2 Financial Performance
8.1.1.3 Service Benchmarking
8.1.1.4 Strategic Initiatives
8.1.2 Eurofins Scientific
8.1.2.1 Company Overview
8.1.2.2 Financial Performance
8.1.2.3 Service Benchmarking
8.1.2.4 Strategic Initiatives
8.1.3 WuXi Biologics
8.1.3.1 Company Overview
8.1.3.2 Financial Performance
8.1.3.3 Service Benchmarking
8.1.3.4 Strategic Initiatives
8.1.4 Samsung Biologics
8.1.4.1 Company Overview
8.1.4.2 Financial Performance
8.1.4.3 Service Benchmarking
8.1.4.4 Strategic Initiatives
8.1.5 Catalent, Inc.
8.1.5.1 Company Overview
8.1.5.2 Financial Performance
8.1.5.3 Service Benchmarking
8.1.5.4 Strategic Initiatives
8.1.6 Rentschler Biopharma SE
8.1.6.1 Company Overview
8.1.6.2 Financial Performance
8.1.6.3 Service Benchmarking
8.1.6.4 strategic Initiatives
8.1.7 AGC Biologics
8.1.7.1 Company Overview
8.1.7.2 Financial Performance
8.1.7.3 Service Benchmarking
8.1.7.4 Strategic Initiatives
8.1.8 Recipharm AB (publ)
8.1.8.1 Company Overview
8.1.8.2 Financial Performance
8.1.8.3 Service Benchmarking
8.1.8 Siegfried Holding AG
8.1.8.1 Company Overview
8.1.8.2 Financial Performance
8.1.8.3 Service Benchmarking
8.1.8.4 Strategic Initiatives
8.1.10 Boehringer Ingelheim
8.1.10.1 Company Overview
8.1.10.2 Service Benchmarking
8.1.10.3 Strategic Initiatives
8.1.11 FUJIFILM Diosynth Biotechnologies
8.1.11.1 Company Overview
8.1.11.2 Financial Performance
8.1.11.3 Service Benchmarking
8.1.11.4 Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of Abbreviation
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in Asia Pacific
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Commodity Flow Analysis
Fig. 14 Volume Price Analysis
Fig. 15 Large Molecule Drug Substance CDMO market snapshot (2022)
Fig. 16 Large Molecule Drug Substance CDMO market segmentation
Fig. 17 Large Molecule Drug Substance CDMO market: Strategy framework
Fig. 18 Parent market outlook
Fig. 19 Related/ancillary market outlook
Fig. 20 Market driver relevance analysis (Current & future impact)
Fig. 21 Current shared services and outsourcing usage levels
Fig. 22 Market restraint relevance analysis (Current & future impact)
Fig. 23 Porter’s five forces analysis
Fig. 24 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 25 Large Molecule Drug Substance CDMO market service outlook: Segment Dashboard
Fig. 26 Large Molecule Drug Substance CDMO market: Service movement analysis
Fig. 27 Contract Manufacturing market, 2018 - 2030 (USD Million)
Fig. 28 Clinical market, 2018 - 2030 (USD Million)
Fig. 29 Commercial market, 2018 - 2030 (USD Million)
Fig. 30 Contract Development market, 2018 - 2030 (USD Million)
Fig. 31 Cell Line Development market, 2018 - 2030 (USD Million)
Fig. 32 Process Development market, 2018 - 2030 (USD Million)
Fig. 33 35 Large Molecule Drug Substance CDMO market source outlook: Segment Dashboard
Fig. 34 Large Molecule Drug Substance CDMO market: Source movement analysis
Fig. 35 Mammalian market, 2018 - 2030 (USD Million)
Fig. 36 Microbial market, 2018 - 2030 (USD Million)
Fig. 37 Others market, 2018 - 2030 (USD Million)
Fig. 38 Large Molecule Drug Substance CDMO market end-user outlook: Segment Dashboard
Fig. 39 Large Molecule Drug Substance CDMO market: End-User movement analysis
Fig. 40 Biotech Companies market, 2018 - 2030 (USD Million)
Fig. 41 CRO market, 2018 - 2030 (USD Million)
Fig. 42 Others (Pharma companies, Government, Research Institutes, Academic Institutes, Etc
Fig. 43 Regional market place: Dashboard
Fig. 44 Large Molecule Drug Substance CDMO Market: Definition & Scope
Fig. 45 Regional Market Snapshot (Figures in USD Million, 2022)
Fig. 46 Regional Market Share, 2022 (USD Million)
Fig. 47 Regional outlook, 2022& 2030
Fig. 48 North America market, 2018 - 2030 (USD Million)
Fig. 49 U.S. market, 2018 - 2030 (USD Million
Fig. 50 Canada market, 2018 - 2030 (USD Million)
Fig. 51 Europe market, 2018 - 2030 (USD Million)
Fig. 52 U.K. market, 2018 - 2030 (USD Million)
Fig. 53 Germany market, 2018 - 2030 (USD Million)
Fig. 54 France market, 2018 - 2030 (USD Million)
Fig. 55 Italy market, 2018 - 2030 (USD Million)
Fig. 56 Spain market, 2018 - 2030 (USD Million)
Fig. 57 Sweden market, 2018 - 2030 (USD Million)
Fig. 58 Denmark market, 2018 - 2030 (USD Million)
Fig. 59 Norway market, 2018 - 2030 (USD Million)
Fig. 60 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 61 Japan market, 2018 - 2030 (USD Million)
Fig. 62 China market, 2018 - 2030 (USD Million)
Fig. 63 India market, 2018 - 2030 (USD Million)
Fig. 64 Australia market, 2018 - 2030 (USD Million)
Fig. 65 Thailand market, 2018 - 2030 (USD Million)
Fig. 66 South Korea market, 2018 - 2030 (USD Million)
Fig. 67 Latin America market, 2018 - 2030 (USD Million)
Fig. 68 Brazil market, 2018 - 2030 (USD Million)
Fig. 69 Mexico market, 2018 - 2030 (USD Million)
Fig. 70 Argentina market, 2018 - 2030 (USD Million)
Fig. 71 MEA market, 2018 - 2030 (USD Million)
Fig. 72 South Africa market, 2018 - 2030 (USD Million)
Fig. 73 Saudi Arabia market, 2018 - 2030 (USD Million)
Fig. 74 UAE market, 2018 - 2030 (USD Million)
Fig. 75 Kuwait market, 2018 - 2030 (USD Million)

Companies Mentioned

  • Thermo Fisher Scientific Inc.
  • Eurofins Scientific
  • Wuxi Biologics
  • Samsung Biologics
  • Catalent, Inc.
  • Rentschler Biopharma Se
  • Agc Biologics
  • Recipharm Ab (Publ)
  • Siegfried Holding AG
  • Boehringer Ingelheim
  • Fujifilm Diosynth Biotechnologies

Methodology

Loading
LOADING...

Related Topics

Related Reports

Global Small Molecule Innovator CDMO Market Size, Share & Trends Analysis Report by Product (Small Molecule API, Small Molecule Drug Product), Stage Type, Customer Type, Therapeutic Area, Region, and Segment Forecasts, 2024-2030 - Product Image

Global Small Molecule Innovator CDMO Market Size, Share & Trends Analysis Report by Product (Small Molecule API, Small Molecule Drug Product), Stage Type, Customer Type, Therapeutic Area, Region, and Segment Forecasts, 2024-2030

  • Report
  • 119 Pages
  • Global
From
Healthcare Contract Development And Manufacturing Organization Market Size, Share & Trends Analysis Report By Services (Contract Development, Contract Manufacturing), By Region, And Segment Forecasts, 2023-2030 - Product Image

Healthcare Contract Development And Manufacturing Organization Market Size, Share & Trends Analysis Report By Services (Contract Development, Contract Manufacturing), By Region, And Segment Forecasts, 2023-2030

  • Report
  • 175 Pages
  • Global
From
Biologics CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Biologics CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 179 Pages
  • Global
From
Global Active Pharmaceutical Ingredients CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2021 - 2029 - Product Image

Global Active Pharmaceutical Ingredients CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2021 - 2029

  • Report
  • 115 Pages
  • Global
From
Active Pharmaceutical Ingredients CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Active Pharmaceutical Ingredients CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 185 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.